Emerging immune checkpoint inhibitors for the treatment of non-small cell lung cancer

References

• Fares CM, Van Allen EM, Drake CG, et al. Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients? ASCO Educ Book. 2019;39:147–164.
   Google Scholar
• Doroshow DB, Sanmamed MF, Hastings K, et al. Immunotherapy in non-small cell lung cancer: facts and hopes. Clin Cancer Res. 2019;25(15):4592–4602.
   PubMed Web of Science ®Google Scholar
• Ding H, Xin W, Tong Y, et al. Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: a systematic review. PLoS One. 2020;15(9):e0238536.
   PubMed Web of Science ®Google Scholar
• Kennedy LC, Bhatia S, Thompson JA, et al. Preexisting autoimmune disease: implications for immune checkpoint inhibitor therapy in solid tumors. J Natl Compr Cancer Netw. 2019;17(6):750–757.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Rodriguez-Abreu D, Robinson AG, et al. KEYNOTE-024 5-year OS update: first-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%. Ann Oncol. 2020;31(suppl_4):S1142–S1215.
   Google Scholar
• Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020;383(14):1328–1339.
   PubMed Web of Science ®Google Scholar
• Burova E, Hermann A, Waite J, et al. Characterization of the anti–pd-1 antibody rEGN2810 and its antitumor activity in human PD-1 knock-in mice. Cancer Ther. 2017;16(5):861–870.
   Google Scholar
• Migden MR, Rischin D, Schmults CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341–351.
   PubMed Web of Science ®Google Scholar
• Sezer A. EMPOWER-Lung 1: phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%. Ann Oncol. 2020;31(suppl_4):S1142–S1215.
   Google Scholar
• Bodarenko I. Clinical benefit of first-line cemiplimab in patients with locally advanced NSCLC: subgroup analysis from EMPOWER-Lung 1. Abstract Session presented at: 2021 WCLC; 2021 Sep 8.
   Google Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–2092.
   PubMed Web of Science ®Google Scholar
• Gray JE, Rodríguez-Abreu D, Powell SF. Pembrolizumab + pemetrexed-platinum for metastatic NSCLC: 4-year follow-up from KEYNOTE-189. Abstract presented at: 2020 World Conference on Lung Cancer; Jan 27; Singapore; 2021.
   Google Scholar
• Garassino MC, Gadgeel S, Esteban E, et al. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(3):387–397.
   PubMed Web of Science ®Google Scholar
• Mark AS, Jotte RM, Cappuzzo F. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–2301.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Nishio M, Jotte RM, et al. IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC. J Thorac Oncol. 2021;16(11):1909–1924.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040–2051.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381(21):2020–2031.
   PubMed Web of Science ®Google Scholar
• Johnson ML, Cho BC, Luft A, et al. Durvalumab ± tremelimumab + chemotherapy as first-line treatment for mNSCLC: results from the phase 3 POSEIDON study. 2021 WCLC; 2021 Sep 8–14.
   Google Scholar
• Paz-Ares L, Ciuleanu T-E, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):198–211.
   PubMed Web of Science ®Google Scholar
• Gogishvili M, Melkadze T, Makharadze T. EMPOWER-Lung 3: cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC). Ann Oncol. 2021;32(suppl_5):S1283–S1346.
   Web of Science ®Google Scholar
• Borghaei H, Gettinger S, Vokes EE, et al. Five-year outcomes from the randomized, phase III trials checkMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2021;39(7):723–733.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–1550.
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–265.
   PubMed Web of Science ®Google Scholar
• Santos ES. Treatment options after first-line immunotherapy in metastatic NSCLC. Expert Rev Anticancer Ther. 2020;20(3):221–228.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342–2350.
   PubMed Web of Science ®Google Scholar
• Hui R, Özgüroğlu M, Villegas A, et al. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(12):1670–1680.
   PubMed Web of Science ®Google Scholar
• Spigel D, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: an update from the PACIFIC trial. J clin oncol. 2021;39(15_suppl):8511.
   Web of Science ®Google Scholar
• Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398(10308): 1344–1357 .
   PubMed Web of Science ®Google Scholar
• Provencio M, Nadal E, Insa A, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(11):1413–1422.
   PubMed Web of Science ®Google Scholar
• Forde PM, Spicer J, LU S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973–1985.
   PubMed Web of Science ®Google Scholar
• Qin S, Xu L, Yi M, et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155.
   PubMed Web of Science ®Google Scholar
• Andre T, Berton D, Curigliano G, et al. Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: results from GARNET study. JCO. 2021;39(3_suppl):9.
   Web of Science ®Google Scholar
• Subramanian J, Moreno V, Bosch-Barrera J, et al. Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC). Ann Oncol. 2020;31:S886–7.
   Google Scholar
• Lu S, Wang J, Cf Yu Y, et al. Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic Nonsquamous NSCLC (RATIONALE 304): a randomized phase 3 trial. J Thorac Oncol. 2021;16(9):1512–1522.
   PubMed Web of Science ®Google Scholar
• Lu S, Huang D, Chen X. RATIONALE 304: tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone as first-line (1L) treatment for non-squamous (non-sq) non-small cell lung cancer (NSCLC) in patients (pts) who are smokers vs non-smokers. Ann Oncol. 2021;32(suppl_5):S949–S1039.
   Google Scholar
• Wang J, Lu S, Yu X, et al. tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2021;7(5):709–717.
   PubMed Web of Science ®Google Scholar
• Xu Y. RATIONALE 307: tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC) in patients (pts) who were smokers vs non-smokers. Ann Oncol. 2021;32(suppl_5):S949–S1039.
   Google Scholar
• Chaudhry A, Johnson M, Colburn D, et al. 1419TiP ARC-7: a phase II study to evaluate the safety and efficacy of zimberelimab alone, AB154 in combination with zimberelimab, and AB154 in combination with zimberelimab and AB928 in front-line, PD-L1 expressing, non-small cell lung cancer (NSCLC). Ann Oncol. 2020;31:S897.
   Web of Science ®Google Scholar
• Washington University School of Medicine. A pilot study to evaluate the safety and efficacy of zimberelimab (AB122) in combination with domvanalimab (AB154) and etrumadenant (AB928) in patients with previously treated non-small cell lung cancer. Report No.: NCT04791839.
   Google Scholar
• Biosciences A. Inc. A phase 3 study to evaluate zimberelimab (AB122) monotherapy compared to standard chemotherapy or zimberelimab combined with Ab154 in front-line, pd-l1-positive, locally advanced or metastatic non-small cell lung cancer. Report No.: NCT04736173.
   Google Scholar
• Zhou C. Updated OS and time to second progression with first-line camrelizumab plus chemo vs chemo for advanced non-squamous NSCLC. Abstract Session presented at: 2020 WCLC; 2021 Jan 28.
   Google Scholar
• Zhou C, Ren S, Chen J. Camrelizumab or placebo plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): a randomized, double-blind, multicenter, phase III trial. J Thorac Oncol. 2021;16(suppl_4):S748–S802.
   Web of Science ®Google Scholar
• Perets R, Bar J, Rasco DW, et al. Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol. 2021;32(3):395–403.
   PubMed Web of Science ®Google Scholar
• Boyer M, Şendur MAN, Rodríguez-Abreu D, et al. Pembrolizumab plus ipilimumab or placebo for metastatic non-small-cell lung cancer with pd-l1 tumor proportion score ≥ 50%: randomized, double-blind phase III KEYNOTE-598 study. J Clin Oncol. 2021;39(21):2327–2338.
   PubMed Web of Science ®Google Scholar
• Zhou C, Wang Z, Sun Y, et al. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. Lancet Oncol. 2022 Feb;23(2):220–233.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Chen M, Jiang O, et al. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2022 Feb;23(2):209–219.
   PubMed Web of Science ®Google Scholar
• Joller N, Hafler JP, Brynedal B, et al. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol. 2011;186(3):1338–1342.
   PubMed Web of Science ®Google Scholar
• Stanietsky N, Simic H, Arapovic J, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci USA. 2009;106(42):17858–17863.
   PubMed Web of Science ®Google Scholar
• Yu X, Harden K, Gonzalez LC, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10(1):48–57.
   PubMed Web of Science ®Google Scholar
• Manieri NA, Chiang EY, Grogan JL. TIGIT: a key inhibitor of the cancer immunity cycle. Trends Immunol. 2017;38(1):20–28.
   PubMed Web of Science ®Google Scholar
• Cho BC, Rodriguez-Abreu D, Hussein M, et al. Updated analysis and Patient-Reported Outcomes (PROs) from CITYSCAPE: a randomised, double-blind, phase II study of the anti-TIGIT antibody Tiragolumab + Atezolizumab (TA) Versus Placebo + Atezolizumab (PA) as first-line treatment for PD-L1+ NSCLC. Ann Oncol. 2021;32(suppl_7):S1428–S1457.
   Google Scholar
• Zhang P, Su DM, Liang M, et al. Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. Mol Immunol. 2008 Mar;45(5):1470–1476.
   PubMed Web of Science ®Google Scholar
• Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105(4):256–265.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Ruiz ME, Vanpouille-Box C, Melero I, et al. Immunological mechanisms responsible for radiation-induced abscopal effect. Trends Immunol. 2018;39(8):644–655.
   PubMed Web of Science ®Google Scholar
• Ahn M, Niu J, Kim D-W. Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC. M. Ann Oncol. 2020;31(suppl_4):S754–S840.
   Google Scholar
• Socinski MA, Spira AI, Paz-Ares LG, et al. AdvanTIG-302: anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC). JCO. 2021;39(15_suppl):9128.
   Web of Science ®Google Scholar
• Huard B, Prigent P, Tournier M, et al. CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. Eur J Immunol. 1995;25(9):2718–2721.
   PubMed Web of Science ®Google Scholar
• Long L, Zhang X, Chen F, et al. The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy. Genes Cancer. 2018;9(5–6):176–189.
   PubMedGoogle Scholar
• He Y, Yu H, Rozeboom L, et al. LAG-3 protein expression in non-small cell lung cancer and its relationship with PD-1/PD-L1 and tumor-infiltrating lymphocytes. J Thorac Oncol. 2017;12(5):814–823.
   PubMed Web of Science ®Google Scholar
• Woo S-R, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012;72(4):917–927.
   PubMed Web of Science ®Google Scholar
• Lipson EJ, Tawbi -HA-H, Schadendorf D, et al. Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: primary phase III results from RELATIVITY-047 (CA224-047). JCO. 2021;39(15_suppl):9503.
   Google Scholar
• Squibb B-M. A phase 2 randomized double-blind study of relatlimab plus nivolumab in combination with chemotherapy vs. nivolumab in combination with chemotherapy as first line treatment for participants with stage IV or recurrent Non-small Cell Lung Cancer (NSCLC). Report No.: NCT04623775. Available from: https://clinicaltrials.gov/ct2/show/NCT04623775.
   Google Scholar
• Felip E, Dober B, Majem M, et al. Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab. JCO. 2020 May 20;38(15 suppl):3100.
   Google Scholar
• McIntire JJ, Umetsu SE, Akbari O, et al. Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nat Immunol. 2001;2(12):1109–1116.
   PubMed Web of Science ®Google Scholar
• Han H, Headley MB, Xu W, et al. Thymic stromal lymphopoietin amplifies the differentiation of alternatively activated macrophages. J Immunol. 2013;190(3):904–912.
   PubMed Web of Science ®Google Scholar
• Koyama S, Akbay EA, Li YY, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7(1):10501.
   PubMed Web of Science ®Google Scholar
• Gros A, Robbins PF, Yao X, et al. PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014;124(5):2246–2259.
   PubMed Web of Science ®Google Scholar
• Baitsch L, Legat A, Barba L, et al. Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS One. 2012;7(2):e30852.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. A randomized, open label phase 2/3 study comparing cobolimab + dostarlimab + docetaxel to dostarlimab + docetaxel to docetaxel alone in participants with advanced nonsmall cell lung cancer who have progressed on prior Anti-PD-(L)1 therapy and chemotherapy (COSTAR Lung). Report No.: NCT04655976.
   Google Scholar
• W HT, Malarkannan S, Wang L. The structure, expression, and multifaceted role of immune-checkpoint protein Vista as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation. Cell Mol Immunol. 2018;15(5):438–446.
   PubMed Web of Science ®Google Scholar
• Le Mercier I, Chen W, Lines JL, et al. Vista regulates the development of protective antitumor immunity. Cancer Res. 2014;74(7):1933–1944.
   PubMed Web of Science ®Google Scholar
• Wang L, Rubinstein R, Lines JL, et al. Vista, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med. 2011;208(3):577–592.
   PubMed Web of Science ®Google Scholar
• Nowak EC, Lines JL, Varn FS, et al. Immunoregulatory functions of Vista. Immunol Rev. 2017;276(1):66–79.
   PubMed Web of Science ®Google Scholar
• Villarroel-Espindola F, Yu X, Datar I, et al. Spatially resolved and quantitative analysis of Vista/PD-1H as a novel immunotherapy target in human non-small cell lung cancer. Clin Cancer Res. 2018;24(7):1562–1573.
   PubMed Web of Science ®Google Scholar
• Suh WK, Gajewska BU, Okada H, et al. The B7 family member B7-H3 preferentially downregulates T helper type 1-mediated immune responses. Nat Immunol. 2003;4(9):899–906.
   PubMed Web of Science ®Google Scholar
• Altan M, Pelekanou V, Schalper KA, et al. B7-H3 expression in NSCLC and its association with B7-H4, PD-L1 and tumor-infiltrating lymphocytes. Clin Cancer Res. 2017;23(17):5202–5209.
   PubMed Web of Science ®Google Scholar
• Yonesaka K, Haratani K, Takamura S, et al. B7-H3 negatively modulates CTL-mediated cancer immunity. Clin Cancer Res. 2018;24(11):2653–2664.
   PubMed Web of Science ®Google Scholar
• Solinas C, Gu-Trantien C, Willard-Gallo K. The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy. ESMO Open. 2020;5(1):e000544.
   PubMed Web of Science ®Google Scholar
• Chan CJ, Martinet L, Gilfillan S, et al. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat Immunol. 2014;15(5):431–438.
   PubMed Web of Science ®Google Scholar
• Martínez-Martí A, Majem M, Barlesi F. COAST: an open-label, randomised, phase II platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC. Ann Oncol. 2021;32(suppl_5):S1283–S1346.
   Google Scholar
• Barrera L, Montes-Servín E, Hernandez-Martinez JM, et al. CD47 overexpression is associated with decreased neutrophil apoptosis/phagocytosis and poor prognosis in non-small-cell lung cancer patients. Br J Cancer. 2017;117(3):385–397.
   PubMed Web of Science ®Google Scholar
• Owonikoko TK, Champiat S, Johnson ML, et al. Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC). JCO. 2021;39(15_suppl):8510.
   Web of Science ®Google Scholar